Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golimumab - Janssen Biotech

Drug Profile

Golimumab - Janssen Biotech

Alternative Names: Anti-TNF-alpha monoclonal antibody - Centocor/Medarex; CNTO-148; MK-8259; SCH 900259; Shinponi; Simponi; SIMPONI ARIA; Simponi Aria; Sympony; Symposony; Xinpini

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centocor; Medarex
  • Developer Centocor; Centocor Ortho Biotech; Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Merck & Co; Mitsubishi Tanabe Pharma Corporation
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antiasthmatics; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II Type 1 diabetes mellitus
  • Phase I/II Hearing disorders
  • Discontinued Asthma; Cardiovascular disorders; Sarcoidosis; Uveitis

Most Recent Events

  • 13 Apr 2023 Janssen completes an expanded access programme for Type-1 diabetes mellitus (In adults, In children) in USA (Subcutaneous), before April 2023 (NCT03945903)
  • 09 Mar 2023 Phase-III clinical trials in Rheumatoid arthritis (Combination therapy, Treatment-experienced) in Lithuania (SC) (EudraCT2022-001825-63 )
  • 28 Dec 2022 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In adolescents, In children, In adults) in Finland (SC, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top